References
- Abbas M, Paul M, Huttner A, New and improved? A review of novel antibiotics for gram-positive bacteria. Clin Microbiol Infect. 2017;23:697–703.
- Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, Hanberger H, et al. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis. 2013;56:798–805.
- Crotty MP, Krekel T, Burnham CA, Ritchie DJ, New gram-positive agents: the next generation of oxazolidinones and lipoglycopeptides. J Clin Microbiol. 2016;54:2225–32.
- Koomanachai P, Crandon JL, Nicolau DP, Newer developments in the treatment of gram-positive infections. Expert Opin Pharmacother. 2009;10:2829–43.
- Munita JM, Bayer AS, Arias CA, Evolving resistance among gram-positive pathogens. Clin Infect Dis. 2015;61: S48–S57.
- Tanwar J, Das S, Fatima Z, Hameed S, Multidrug resistance: an emerging crisis. Inter Perspect Infect Dis. 2014;2014. Article ID: 541340.
- Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016;37:1288–301.
- Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS, Antimicrobial resistance. JAMA. 2016;316:1193–204.
- Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE, Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. Diagn Microbiol Infect Dis. 2018;91:199–204.
- Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015;75:253–70.
- Locke JB, Zurenko GE, Shaw KJ, Bartizal K, Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis. 2014;58: S35–S42.
- Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, et al. Results of the surveillance of tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis. 2015;81:112–8.
- Pfaller MA, Flamm RK, Jones RN, Farrell DJ, Mendes RE, Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014. Antimicrob Agents Chemother. 2016;60:5393–9.
- Bensaci M, Sahm D, Surveillance of tedizolid activity and resistance: in vitro susceptibility of gram-positive pathogens collected over 5 years from the United States and Europe. Diagn Microbiol Infect Dis. 2017;87:133–8.
- CLSI. M07Ed11E. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 11th edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
- Breakpoint tables for interpretation of MIC's and zone diameters. Version 8.0, January 2018 [Internet]. European Committee on Antimicrobial Susceptibility Testing. 2018 [cited January 2018]. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_8.0_Breakpoint_Tables.pdf.
- Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G, Use of linezolid susceptibility test results as a surrogate for the susceptibility of gram-positive pathogens to tedizolid, a novel oxazolidinone. Ann Clin Microbiol Antimicrob. 2014;13:46.